SMO Clinplus Co (SZSE:301257) ROCE %: -2.56% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301257 SMO Clinplus Co Ltd SZSE:301257
91 GF Score
Price ¥35.17
GF Value ¥38.90
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is SMO Clinplus Co ROCE %?

SMO Clinplus Co SZSE:301257 -4.95% 91 ROCE % is -2.56% as of Jun. 2026. GuruFocus rates SZSE:301257 with a GF Score™ of 91/100 and a GF Value™ of ¥38.90 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SMO Clinplus Co's annualized ROCE % for the quarter that ended in Jun. 2026 was -2.56%.

SMO Clinplus Co  (SZSE:301257) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SMO Clinplus Co ROCE % Related Terms

SMO Clinplus Co ROCE % Historical Data

* Premium members only.

The historical data trend for SMO Clinplus Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SMO Clinplus Co ROCE % Chart

SMO Clinplus Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.82 13.71 15.83 10.80 10.48

SMO Clinplus Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.78 12.24 9.30 3.88 -2.56
SZSE:301257
91GF Score
SMO Clinplus Co Ltd SZSE:301257
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SMO Clinplus Co ROCE % Calculation

SMO Clinplus Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=128.077/( ( (1429.62 - 255.781) + (1543.918 - 273.801) )/ 2 )
=128.077/( (1173.839+1270.117)/ 2 )
=128.077/1221.978
=10.48 %

SMO Clinplus Co's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-32.664/( ( (1524.903 - 242.383) + (1529.962 - 263.309) )/ 2 )
=-32.664/( ( 1282.52 + 1266.653 )/ 2 )
=-32.664/1274.5865
=-2.56 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -2.56% mean?
SMO Clinplus Co (SZSE:301257) has a ROCE % of -2.56% as of Jun. 2026.
Is SMO Clinplus Co's ROCE % too high?
SMO Clinplus Co's current ROCE % is -2.56%. Overall, SMO Clinplus Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SMO Clinplus Co's ROCE % compare to TMO and DHR?
SMO Clinplus Co's ROCE % of -2.56% can be compared against companies in the Medical Diagnostics & Research industry. The industry median ROCE % is 0.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
The median ROCE % among Medical Diagnostics & Research companies is 0.50, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median ROCE % is 0.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMO Clinplus Co's current ROCE % is -2.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMO Clinplus Co stock overvalued right now?
Based on GuruFocus' analysis, SMO Clinplus Co (SZSE:301257) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.90, compared to a current price of ¥35.17 — trading 9.6% below its estimated fair value. The current ROCE % is -2.56%. SMO Clinplus Co's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SMO Clinplus Co (SZSE:301257), the current ROCE % is -2.56% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SMO Clinplus Co (SZSE:301257) Overvalued in 2026?

Based on GuruFocus' analysis, SMO Clinplus Co stock appears to be undervalued. The current stock price of ¥35.17 is trading 9.6% below its estimated GF Value™ of ¥38.90. GuruFocus considers SMO Clinplus Co to be Modestly Undervalued.

Key valuation signals for SZSE:301257:

  • ROCE %: -2.56%
  • GF Value™: ¥38.90 vs. price of ¥35.17 (9.6% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the SZSE:301257 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SMO Clinplus Co Business Description

Address 500 Guangdong Road, 23rd Floor, World Trade Building, Huangpu District, Shanghai, CHN, 200001
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies, and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
91GF Score

Get the complete analysis for SZSE:301257

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥35.17
Price
¥38.90
GF Value